HLA-A02 TP53-R175H targeting T cell engager - Affini-T Biotherapeutics
Alternative Names: P53 R175H targeting bispecific T cell engager - Affini-T Biotherapeutics ; T cell engager targeting HLA-A 02 01 TP53-R175H - Affini-T BiotherapeuticsLatest Information Update: 30 Jul 2025
At a glance
- Originator Affini-T Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer